Melvin LK CHUA
@DrMLChua
Chair, HN&Thorax Cancers | Clinician-Scientist @NCCS | Lead PI #NPC RIBBON-LA trial (NCT05517135) | Clinical Trials Chair @HNCIG | @Alicesarc | @ASCO #ASCOBT24
ID:832473385871384576
http://www.chualabnccs.com 17-02-2017 06:14:56
2,0K Tweets
1,3K Followers
313 Following
What I learned in 🇨🇱 today … $5mill = one #radiotherapy machine☢️, can treat 10k patients. $5mill = 135 patients worth of trastuzumab. 🧐
The Lancet Oncology - tinyurl.com/6bry9a2a “an essential pillar in multi-D oncology…an inexpensive modality” - 👏🏽 well said Targeting Cancer
Submit an abstract by 11:59 PM ET April 9 for ASCOBT24 - Lillian Siu
ASCO Melvin LK CHUA
oncodaily.com/43901.html
#ASCO #ASCO BT24 #Cancer #OncoDaily #Oncology
11 days to submit your abstracts for #ASCOBT24
Deadline 9 April 2024 US ET!
We are all inclusive for #CancerResearch
#CancerCare
#TranslationalResearch
#ClinicalTrials
#Innovation
Check out the amazing line-up of speakers! Lillian Siu ASCO
conferences.asco.org/breakthrough/p…
#ICHNO24
Honoured to deliver the Keynote lecture on ctDNA in #headandneckcancer
Thanks to great colleagues Eleni Rettig Linda Chen Nancy Lee who were generous to share their data and insights on the trials using ctDNA guided treatment and FU in #HPVOPSCC
Much to be learnt!
Limitations of ctDNA 🩸use in #HPV + #HNSCC : beware of false negs if low baseline ctDNA, can not be used for tx deescalation. Melvin LK CHUA on 🔥 #ICHNO2024
Spoiler alert! 🔴 #ICHNO24
University Health Network University of Toronto Prof Sophie Huang espousing on the integration of iENE in staging and risk stratification in #headandneckcancer
Great work by Christina Henson, MD Lachlan McDowell Head and Neck Cancer International Group
Expect it to be part of upcoming new staging editions! 😄
Excellent talk by Brigette Ma summarizing the progress over time in nasopharyngeal cancer treatment and current guidelines. At #ICHNO2024
Happening at #ICHNO24
Wonderful Keynote lecture by Prof_Brigette Ma CUHK Medicine on the changing landscape of #NPC #nasopharyngealcarcinoma
Nice summary of all the clinical and translational advances over the decades! Highlights the impressive number of RCTs over the years!
Great hosting the team from University of Michigan this morning and showcasing our Precision Radiotherapeutic Oncology Programme
Thanks for visiting Daniel Chang! Hope you enjoy your rest of the time in 🇸🇬 Weather and food are great! 😜
#GlobalHealth
#Collaboration
#RadiationOncology
This is amazing!! Very very stoked for Lillian Siu
Who better person to lead AACR with its broad membership to be able to focus on all the needs of #CancerResearch from trials to translational-basic research to cost, Advance Care AND advocate for #Diversity
This is a massive and timely undertaking to push for a new stage classification in #NPC #nasopharyngealcarcinoma
Look out for the updated 9th ed staging in due course w Pierre Blanchard, MD
cell.com/cancer-cell/fu…
Check out the beautiful cover art!
Speaking world tour of 3 countries, 5 cities in 11 days!!! In between running clinics and planning treatments! 😂😂
Didn’t imagine I wuld survive such a feat but Impt to showcase the work we do in #Nosecancer #NasopharyngealCancer at NCCS
Very thankful of my Team &Family!
Pleasure to have Melvin LK CHUA sharing his insights on personalised approach for NPC at Faculty of Medicine, Universiti Malaya at the NPC Research Day.
Do submit your abstracts to #ASCOBT24
Deadline in a month 9 Apr 2024!
asco.confex.com/asco/bts2024/c…
Listen to Dr. Yan Leyfman on Why You Should Submit to #ASCOBT24 ASCO Lillian Siu Hidehito HORINOUCHI Naoto T Ueno, MD, PhD
youtu.be/PEQjfaCN59Y?si… via YouTube
Disparate de-escalation strategies in HPV+ OPSCC #HNCS24
For PORT: de-escalation by path results
For CRT: de-escalation by on treatment response
Who’s the winner and what’s the way forward? 🤔
Nadeem Riaz Nancy Lee C. Jillian Tsai, MD, PhD Daniel Ma